Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society

Volumn 160, Issue 2, 2008, Pages 99-100

  Sartor, Oliver ^a  

^a Stanley Scott Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; LEUPRORELIN; NITRILE; PROSTATE SPECIFIC ANTIGEN; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ARTICLE; BLOOD; CANCER STAGING; CASE REPORT; DISEASE COURSE; DRUG COMBINATION; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE TUMOR; TIME;

ANILIDES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TOSYL COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649182112     PISSN: 00246921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)